Ann Dermatol.  2010 Feb;22(1):81-84. 10.5021/ad.2010.22.1.81.

A Case of Complication after Matridex(R) Injection

• Huh SY
• Cho S
• Kim KH
• An JS
• Won CH
• Chang SE
• Lee MW
• Choi JH
• Moon KC

• KMID: 2172046
• DOI: http://doi.org/10.5021/ad.2010.22.1.81

Abstract

Matridex(R) is an injectable skin filler that's composed of a mixture of cross linked hyaluronic acid and dextranomer particles, and it was recently developed for soft tissue augmentation. To the best of our knowledge, there have been few previous reports on complications associated with Matridex. We report here on a delayed inflammatory reaction to an injection of Matridex in the glabellar fold, and this developed five weeks after the injection and it lasted more than a year. The patient was treated with oral doxycycline and intralesional injection of triamcinolone acetonide; this resulted in almost complete resolution of the lesion. The patient should be informed of the potential complications with the use of injectable fillers before treatment, for it could lead to undesirable aesthetic consequences.

Keyword

Complication; Delayed inflammatory reaction; Filler; Matridex

MeSH Terms

Dextrans
Doxycycline
Humans
Hyaluronic Acid
Injections, Intralesional
Skin
Triamcinolone
Dextrans
Doxycycline
Hyaluronic Acid
Triamcinolone

Figure

• 

  Fig. 1 (A) A solitary indurated erythematous nodule with a smooth surface in the right-side glabellar fold. (B) The lateral view of the lesion.

• 

  Fig. 2 A moderate lymphohistiocytic infiltration involving the muscle layer and the sub-muscle layer, and this was accompanied by fibrosis that was most prominent in the sub-muscle layer (A: H&E, ×40; B: H&E, ×100).

• 

  Fig. 3 After 3 months of treatment with oral doxycycline and intralesional triamcinolone acetonide injection, substantial improvement of the lesion was observed.

Reference

1. Eppley BL, Summerlin DJ, Prevel CD, Sadove AM. Effects of a positively charged biomaterial for dermal and subcutaneous augmentation. Aesthetic Plast Surg. 1994. 18:413–416.

2. Massone C, Horn M, Kerl H, Ambros-Rudolph CM, Giovanna Brunasso AM, Cerroni L. Foreign body granuloma due to Matridex injection for cosmetic purposes. Am J Dermatopathol. 2009. 31:197–199.

3. Lemperle G, Morhenn V, Charrier U. Human histology and persistence of various injectable filler substances for soft tissue augmentation. Aesthetic Plast Surg. 2003. 27:354–367.

4. Lowe NJ, Maxwell CA, Lowe P, Duick MG, Shah K. Hyaluronic acid skin fillers: adverse reactions and skin testing. J Am Acad Dermatol. 2001. 45:930–933.

5. Friedman PM, Mafong EA, Kauvar AN, Geronemus RG. Safety data of injectable nonanimal stabilized hyaluronic acid gel for soft tissue augmentation. Dermatol Surg. 2002. 28:491–494.

6. Micheels P. Human anti-hyaluronic acid antibodies: is it possible? Dermatol Surg. 2001. 27:185–191.

7. Duranti F, Salti G, Bovani B, Calandra M, Rosati ML. Injectable hyaluronic acid gel for soft tissue augmentation. A clinical and histological study. Dermatol Surg. 1998. 24:1317–1325.

8. Manna F, Dentini M, Desideri P, De Pita O, Mortilla E, Maras B. Comparative chemical evaluation of two commercially available derivatives of hyaluronic acid (hylaform from rooster combs and restylane from streptococcus) used for soft tissue augmentation. J Eur Acad Dermatol Venereol. 1999. 13:183–192.

9. Brody HJ. Use of hyaluronidase in the treatment of granulomatous hyaluronic acid reactions or unwanted hyaluronic acid misplacement. Dermatol Surg. 2005. 31:893–897.

10. Lloret P, Espana A, Leache A, Bauza A, Fernandez-Galar M, Idoate MA, et al. Successful treatment of granulomatous reactions secondary to injection of esthetic implants. Dermatol Surg. 2005. 31:486–490.

11. Bachelez H, Senet P, Cadranel J, Kaoukhov A, Dubertret L. The use of tetracyclines for the treatment of sarcoidosis. Arch Dermatol. 2001. 137:69–73.